Literature DB >> 22739839

Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Seithikurippu R Pandi-Perumal1, Ahmed S BaHammam, Gregory M Brown, D Warren Spence, Vijay K Bharti, Charanjit Kaur, Rüdiger Hardeland, Daniel P Cardinali.   

Abstract

The pineal product melatonin has remarkable antioxidant properties. It is secreted during darkness and plays a key role in various physiological responses including regulation of circadian rhythms, sleep homeostasis, retinal neuromodulation, and vasomotor responses. It scavenges hydroxyl, carbonate, and various organic radicals as well as a number of reactive nitrogen species. Melatonin also enhances the antioxidant potential of the cell by stimulating the synthesis of antioxidant enzymes including superoxide dismutase, glutathione peroxidase, and glutathione reductase, and by augmenting glutathione levels. Melatonin preserves mitochondrial homeostasis, reduces free radical generation and protects mitochondrial ATP synthesis by stimulating Complexes I and IV activities. The decline in melatonin production in aged individuals has been suggested as one of the primary contributing factors for the development of age-associated neurodegenerative diseases. The efficacy of melatonin in preventing oxidative damage in either cultured neuronal cells or in the brains of animals treated with various neurotoxic agents, suggests that melatonin has a potential therapeutic value as a neuroprotective drug in treatment of Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), stroke, and brain trauma. Therapeutic trials with melatonin indicate that it has a potential therapeutic value as a neuroprotective drug in treatment of AD, ALS, and HD. In the case of other neurological conditions, like PD, the evidence is less compelling. Melatonin's efficacy in combating free radical damage in the brain suggests that it can be a valuable therapeutic agent in the treatment of cerebral edema following traumatic brain injury or stroke. Clinical trials employing melatonin doses in the range of 50-100 mg/day are warranted before its relative merits as a neuroprotective agent is definitively established.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22739839     DOI: 10.1007/s12640-012-9337-4

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  339 in total

Review 1.  Variability of interactions between neuroendocrine and immunological functions in physiological aging and dementia of the Alzheimer's type.

Authors:  E Ferrari; M Fioravanti; F Magri; S B Solerte
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

2.  Melatonin treatment of day-night rhythm disturbances and sundowning in Alzheimer disease: an open-label pilot study using actigraphy.

Authors:  Richard Mahlberg; Dieter Kunz; Igor Sutej; Klaus-Peter Kühl; Rainer Hellweg
Journal:  J Clin Psychopharmacol       Date:  2004-08       Impact factor: 3.153

3.  Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study.

Authors:  Camila Andrade Mendes Medeiros; Pedro Felipe Carvalhedo de Bruin; Lívia Ariane Lopes; Maria Cecília Magalhães; Maria de Lourdes Seabra; Veralice Meireles Sales de Bruin
Journal:  J Neurol       Date:  2007-04-03       Impact factor: 4.849

Review 4.  Brain aging, Alzheimer's disease, and mitochondria.

Authors:  Russell H Swerdlow
Journal:  Biochim Biophys Acta       Date:  2011-09-02

5.  Melatonin reduces quinolinic acid-induced lipid peroxidation in rat brain homogenate.

Authors:  G Southgate; S Daya
Journal:  Metab Brain Dis       Date:  1999-09       Impact factor: 3.584

6.  Evidence that membrane-bound G protein-coupled melatonin receptors MT1 and MT2 are not involved in the neuroprotective effects of melatonin in focal cerebral ischemia.

Authors:  Ulkan Kilic; Bayram Yilmaz; Milas Ugur; Adnan Yüksel; Russel J Reiter; Dirk M Hermann; Ertugrul Kilic
Journal:  J Pineal Res       Date:  2011-09-14       Impact factor: 13.007

Review 7.  Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders.

Authors:  Mathias Jucker; Lary C Walker
Journal:  Ann Neurol       Date:  2011-10       Impact factor: 10.422

8.  Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors.

Authors:  Angela M Floden; Shanshan Li; Colin K Combs
Journal:  J Neurosci       Date:  2005-03-09       Impact factor: 6.167

9.  Melatonin treatment improves the antioxidant status and decreases lipid content in brain and liver of rats.

Authors:  Perumal Subramanian; Shankaran Mirunalini; Seithikurippu R Pandi-Perumal; Ilya Trakht; D P Cardinali
Journal:  Eur J Pharmacol       Date:  2007-06-21       Impact factor: 4.432

10.  Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease.

Authors:  Philip R Gehrman; Donald J Connor; Jennifer L Martin; Tamar Shochat; Jody Corey-Bloom; Sonia Ancoli-Israel
Journal:  Am J Geriatr Psychiatry       Date:  2009-02       Impact factor: 4.105

View more
  71 in total

Review 1.  Transcriptional control of antioxidant defense by the circadian clock.

Authors:  Sonal A Patel; Nikkhil S Velingkaar; Roman V Kondratov
Journal:  Antioxid Redox Signal       Date:  2014-01-03       Impact factor: 8.401

2.  Melatonin Alleviates the Epilepsy-Associated Impairments in Hippocampal LTP and Spatial Learning Through Rescue of Surface GluR2 Expression at Hippocampal CA1 Synapses.

Authors:  Yue Ma; Xiaolong Sun; Juan Li; Ruihua Jia; Fang Yuan; Dong Wei; Wen Jiang
Journal:  Neurochem Res       Date:  2017-02-18       Impact factor: 3.996

Review 3.  Expression and putative functions of melatonin receptors in malignant cells and tissues.

Authors:  Cem Ekmekcioglu
Journal:  Wien Med Wochenschr       Date:  2014-07-15

4.  Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.

Authors:  Juan Segura-Aguilar; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2015-01-29       Impact factor: 3.911

5.  The muscarinic effect of anhydroecgonine methyl ester, a crack cocaine pyrolysis product, impairs melatonin synthesis in the rat pineal gland.

Authors:  Lívia Silva Medeiros de Mesquita; Raphael Caio Tamborelli Garcia; Fernanda Gaspar Amaral; Rafael Peres; Simone Miller Wood; RodrigoVincenzo de Luca Lucena; Eduardo Osório Frare; Mariana Vieira Abrahão; Tania Marcourakis; José Cipolla-Neto; Solange Castro Afeche
Journal:  Toxicol Res (Camb)       Date:  2017-03-29       Impact factor: 3.524

Review 6.  The implication of neuronimmunoendocrine (NIE) modulatory network in the pathophysiologic process of Parkinson's disease.

Authors:  Yan Shen; Xingfang Guo; Chao Han; Fang Wan; Kai Ma; Shiyi Guo; Luxi Wang; Yun Xia; Ling Liu; Zhicheng Lin; Jinsha Huang; Nian Xiong; Tao Wang
Journal:  Cell Mol Life Sci       Date:  2017-06-16       Impact factor: 9.261

7.  Kynurenine, a Tryptophan Metabolite That Accumulates With Age, Induces Bone Loss.

Authors:  Mona El Refaey; Meghan E McGee-Lawrence; Sadanand Fulzele; Eileen J Kennedy; Wendy B Bollag; Mohammed Elsalanty; Qing Zhong; Ke-Hong Ding; Nathaniel G Bendzunas; Xing-Ming Shi; Jianrui Xu; William D Hill; Maribeth H Johnson; Monte Hunter; Jessica L Pierce; Kanglun Yu; Mark W Hamrick; Carlos M Isales
Journal:  J Bone Miner Res       Date:  2017-08-14       Impact factor: 6.741

8.  Therapeutic application of melatonin in mild cognitive impairment.

Authors:  Daniel P Cardinali; Daniel E Vigo; Natividad Olivar; María F Vidal; Analía M Furio; Luis I Brusco
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

Review 9.  Melatonin and Multiple Sclerosis: From Plausible Neuropharmacological Mechanisms of Action to Experimental and Clinical Evidence.

Authors:  Mahshid Yeganeh Salehpour; Adriano Mollica; Saeideh Momtaz; Nima Sanadgol; Mohammad Hosein Farzaei
Journal:  Clin Drug Investig       Date:  2019-07       Impact factor: 2.859

10.  Exogenous melatonin for sleep disorders in neurodegenerative diseases: a meta-analysis of randomized clinical trials.

Authors:  Wei Zhang; Xue-Yan Chen; Su-Wen Su; Qing-Zhong Jia; Tao Ding; Zhong-Ning Zhu; Tong Zhang
Journal:  Neurol Sci       Date:  2015-08-09       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.